

P&G Case AA537C

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of

Chie Ohba

Confirmation No.

Serial No. To Be Assigned

: Group Art Unit

Filed July 2, 2003

Examiner

For Absorbent Interlabial Device

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents

P. O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, record is being made below in a Form PTO/SB08 of documents which the Patent Office may wish to consider in connection with examination of the above-identified patent application. It is respectfully requested that the cited documents be carefully considered by the Examiner and made of record in this case. As provided in §1.97(g), no representation is made or intended that a thorough art search was made. As provided in 37 C.F.R. §1.97(h), this Information Disclosure Statement does not constitute an admission of any kind, and specifically is not an admission that the documents listed on attached form PTO/SB08 are, or are considered to be, material to the patentability of the above-identified patent application, as defined in 37 C.F.R. §1.56(b).

1. [X] 37 C.F.R. $\S1.97$ (b)(1) - U.S. Direct (within 3-months of filing a regular application or converted provisional)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(1), is being filed within three months of the filing date of a national application. Therefore, no fee is believed to be due.

2. [] 37 C.F.R. §1.97 (b)(2) - Via PCT (within 3 mo. of Nat'l Stage Entry)

This information disclosure statement, submitted under 37 C.F.R. §1.97 (b)(2), is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application. Therefore, no fee is believed to be due.

3. [] 37 C.F.R. §1.97 (b)(3) - (>3 mo. after filing direct or nat'l stage entry, but before 1st O.A.)

This information disclosure statement is being submitted under 37 C.F.R. §1.97 (b)(3). Applicants have not received an Office Action on the merits in the present application. Therefore, no fee is believed to be due. However, in the event that this paper is crossing in the mail with a first Office Action on the merits, authorization is hereby given to charge the required fee pursuant of 37 C.F.R. §1.97(c) and 37 C.F.R. §1.17(p) to Deposit Account No. 16-2480 in the name of The Procter & Gamble Company. A duplicate of this letter is enclosed to facilitate charging of the fee, if necessary.

THE FOLLOWING IS ADDITIONAL INFORMATION PERTAINING TO (2) OR (3) MARKED WITH AN (X) ABOVE.

- (a) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that <u>both</u> a copy of the International Search Report and copies of the references cited therein are present in the national stage file. In accordance with MPEP §1893.03(g), it is respectfully requested that the Examiner note the consideration of these references in the first Office Action via the PTO-892 form.
- (b) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 indicates that a copy of the International Search Report is present in the national stage file. Copies of the references cited in that report are enclosed.
- (c) [] The Notification of Acceptance of this Application Under 35 U.S.C. §371 does <u>not</u> indicate that a copy of the International Search Report and copies of the references cited are present in the national stage file. Copies of the International Search Report and references are attached.
- 4. [] 37 C.F.R. §1.97 (b)(4) (before the mailing of a first Office Action after the filing of a request for continued examination under §1.114)

This information disclosure statement, submitted under 37 C.F.R. §1.97(b)(4), is being filed with the Request for Continued Examination (RCE) under 37 C.F.R. §1.114.

5. [] Information to be Considered with CPA Filing. This information disclosure statement is being filed with a Continued Prosecution Application (CPA) filed under 37 CFR 1.53(d).

6. [] 37 C.F.R. §1.97(c) with fee payment - (use after 1" Office Acti n & before Final Office Action or Notice of Allowance)

This information disclosure statement is being submitted under 37 C.F.R. §1.97(c). Applicant(s) have not received a final action under 37 C.F.R. §1.113, a notice of allowance under 37 C.F.R. §1.311, or an action that otherwise closes prosecution in the application (e.g., Ex parte Quayle) as of the date of this submission. Applicant(s) elect to pay the fee set forth in 37 C.F.R. §1.17(p). Please charge the fee set forth in 37 C.F.R. §1.17(p) to Deposit Account Number 16-2480 in the name of The Procter & Gamble Company. A duplicate copy of this letter (or a fee transmittal form) is enclosed to facilitate the charging of the fee.

ADDITIONAL ITEMS TO BE NOTED BY THE EXAMINER:

[] (1) Copies of the cited references were previously cited by or submitted to the USPTO
in prior application Case No, U.S. Patent Application Serial No, filed Applicants
claim priority to said application under 35 U.S.C. §120. Accordingly, copies of those documents
are not provided with this Statement, pursuant to 37 C.F.R. §1.98(d).
OR
[X] (2) Copies of the cited documents are enclosed.
OR
(3) Copies of all said documents, except document No.'s, were submitted
and considered in parent application U.S. Patent Application Serial No, filed
. Applicant(s) claim priority to said application under 35 U.S.C. §120. Accordingly,
copies of document No.'s are not provided with this Statement, pursuant
to 37 C.F.R. §1.98(d). Copies of document No.'s are enclosed. It is
respectfully requested that the cited documents be carefully considered by the Examiner and
made of record in this case.
[] (4) Pursuant to 37 C.F.R. §1.98(c), a concise explanation of the relevance of each cited
reference that is not in the English language is provided.
[] (5) Applicants also respectfully request the Examiner to consider and make of record
the copending applications listed on the attached page.

[]Additional information is attached.

Respectfully submitted,

Keyin C. Johnson Attorney or Agent for Applicant(s) Registration No. 35,558

(513) 634-3849

Date: July 2, 2003

Customer No. 27752

(IDS.doc) (Last Revised 4/4/2003)

SHEET 1 of 1

Approved for use through 04/30/2003. OMB 0651-0031
Patent and Trademark Office; U. S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO COMPLETE IF KNOWN

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

to a collection of information unles	s it contains a valid OMB control number
COMPI	LETE IF KNOWN
Application Number	To Be Assigned
Confirmation Number	To Be Assigned
Filing Date	July 2, 2003
First Named Inventor	Chie Ohba
Group Art Unit	To Be Assigned
Examiner Name	To Be Assigned
Attorney Docket Number	AA537C

U. S. PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	DOCUMENT NUMBER Number - Kind Code ² (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear
		US-2,092,346	09-07-1937	Arone	
	$\overline{}$	US-2,662,527	12-15-1953	Jacks	
		US-2,917,049	12-15-1959	Delaney	
		US-3,420,235	01-07-1969	Harmon	
		US-3,856,013	12-24-1974 -	Dulle	
		US-3,905,372	09-16-1975	Denkinger	
		US-4,595,392	06-17-1986 —	Johnson	
		US-4,631,062	12-23-1986 —	Lassen	
		US-5,389,181	ر 02-14-1995	Vukos	
		US-5,961,508	10-05-1999 🔾	Mayer	

FOREIGN PATENT DOCUMENTS

EXAMINER INITIALS*	Cite No.1	FOREIGN PATENT DOCUMENT Country Code ³ Number ⁴ Kind Code ³ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines Where Relevant Passages or Relevant Figures Appear	T ⁴
		DE 4,032,119 A1 :	04-16-1992	Bortz		X
		FR 2,703,244 A	10-07-1994	Lefebvre		X
		NL 1004631 💟	10-02-1997	Winkels		X
	1	WO 99/55270 A1	11-04-1999	Gann		
		WO 00/40197 A1 ~	07-13-2000	Lichstein		

NON PATENT LITERATURE DOCUMENTS

EXAMINER INITIALS*	Cite No.1		
EXAMINE	₹	DATE CONSIDERED	_

EXAMINER: Initial if reference considered, whether or not citation is in conformance with M.P.E.P. 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). See kind Codes of U.S. Patient Documents at www.upsi.gov or MPEP 901.04. ¹Enter Office that issue the document, by the two-letter code (WPIPO Standard ST.3). ¹For Japensee patient documents, the finds of the year of the riging of the Emperor must procede the serial number of the patient document. ¹Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.1.6 If possible. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vany depending upon the needs of the individual case. Afty comments on the amount of time you are required to complete his form should be sent to the Chief Information Officer, Petent and Trademack Office. Washington, D. C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA. 22313-1450, VA. 22313-1450, VA. 22313-1450.